Core Insights - Bio-Techne has a rich history of 50 years, with a core business that includes 7,000 proteins and 400,000 antibodies, serving as essential components for life science tools and laboratory research [2] - Over the past decade, Bio-Techne has focused on leveraging its components in faster-growing application areas, specifically in cell therapy and proteomics [3] Application Areas - The first application area is cell therapy, which involves growing immune or regenerative cells to treat diseases, supported by the necessary core components and bioreactor technology [3] - The second application area is proteomics, which is centered around proteomic analysis, although further details were not provided in the excerpt [4]

Question-and-Answer SessionAwesome. So lots to get into here. I would love to just start off on 3Q performance. So I think you guys delivered 18% organic growth, double-digit growth across every franchise. Can you just talk about some of the drivers of this performance? Were there any standout products or customer categories to call out?Jason GarlandCFO & Chief Compliance Officer Yes. We were really happy with the quarter. Again, just the continued momentum that we've seen through the year. As you said, it ...

Core Insights - Repligen Corporation (RGEN) reported third-quarter 2025 adjusted earnings per share of 46 cents, exceeding the Zacks Consensus Estimate of 42 cents and up from 43 cents in the same quarter last year [1][5] - Total revenues for the third quarter reached $189 million, reflecting a 22% year-over-year increase, and beating the Zacks Consensus Estimate of $181 million [2][5] - Despite strong earnings and revenue growth, shares of Repligen fell 5.9% on October 28 following the results announcement [2] Financial Performance - Product revenues were $188.8 million, up nearly 21.9% from the previous year, while royalty and other revenues were $0.04 million, up 5.4% year over year [3] - Organic non-COVID revenue growth was reported at 18%, with total orders growing over 20% year over year across all franchises [4] - Adjusted gross margin improved to 53.3%, an increase of 260 basis points year over year, while adjusted operating income rose 16% to $26.8 million [7] Guidance and Outlook - Repligen raised its 2025 revenue outlook to a range of $729-$737 million, up from the previous expectation of $715-$735 million, and organic revenue growth is now projected at 12%-13.5% [9] - The company tightened its adjusted EPS guidance to a range of $1.65 to $1.68, down from $1.65 to $1.72, which may have negatively impacted investor sentiment [10] - Adjusted operating margin was reported at 14.2%, slightly lower than 14.9% in the same quarter last year [8] Market Position - As of September 30, 2025, Repligen had cash and cash equivalents of $749 million, an increase from $709 million as of June 30, 2025 [8] - The company currently holds a Zacks Rank 4 (Sell), while other biotech stocks like ANI Pharmaceuticals, Beam Therapeutics, and CorMedix have better rankings [12]

Group 1: Lam Research Corporation - Lam Research reported revenues of $5.17 billion and a gross margin of 50.1% for the quarter ending June 2025, with net income rising to $1.72 billion or $1.35 per diluted share, up from $1.03 in the prior quarter [1] - The company expects revenues around $5.2 billion next quarter, with earnings per share near $1.20, indicating continued strength in its core business [1] - Lam Research's stock has climbed 34.72% over the past year, with a strong 41% gain so far in 2025, reflecting growing confidence in the demand for advanced chips [3] - The company announced a quarterly dividend of $0.26 per share, up from $0.23, payable on October 15, 2025, marking its commitment to returning value to shareholders [6] - Lam Research continues to innovate with the launch of the ALTUS Halo tool for advanced chip production and has invested in Zettabyte, focusing on the growing AI market [7] Group 2: Ingredion Incorporated - Ingredion increased its quarterly payout to $0.82 per share on August 27, 2025, reflecting a commitment to returning value to shareholders [5] - The company reported a 13% jump in operating income to $271 million in Q2 2025, with earnings per share rising to $2.99 from $2.22 in the previous year [11] - Ingredion's stock has declined by 5.17% over the past year, but it offers a dividend yield of 2.5% and has increased dividends for 15 consecutive years, indicating potential value for investors [10] - The company is expanding its partnership with Univar Solutions to distribute plant-based ingredients and is investing $50 million to enhance its Cedar Rapids facility, showing a focus on growth beyond food ingredients [12] Group 3: Nordson Corporation - Nordson reported sales of $742 million in Q3 2025, a 12% increase compared to the prior year, with adjusted earnings per share jumping 13% to $2.73 [17] - The company offers a dividend yield of 1.04% and has increased dividends for 63 straight years, with a payout ratio under 30% [16] - Analysts are positive on Nordson's future, with all surveyed giving it a consensus "Moderate Buy" rating and an average price target of $256.44, indicating roughly 15% upside from the current price [19] Group 4: Market Overview - Recent dividend increases from Lam Research, Ingredion, and Nordson indicate confidence in their ability to generate steady cash flows amid uncertain economic conditions [20] - The semiconductor equipment sector, represented by Lam Research, shows strong growth potential, while Ingredion combines growth with a focus on healthier food options [20]

Financial Data and Key Metrics Changes - The company reported second quarter revenue of $182 million, reflecting a 15% increase year-over-year, with an 11% organic growth excluding acquisitions and currency effects, and a 17% organic non-COVID growth [26][27] - Adjusted income from operations was $22 million, up 8% year-over-year, with an adjusted operating margin of 12%, down 80 basis points from the previous year [30][31] - Adjusted fully diluted earnings per share for the second quarter were $0.37, down 6% year-over-year [32] Business Line Data and Key Metrics Changes - Chromatography revenue grew over 40%, driven by large-scale column demand from Pharma and Europe, while filtration revenue grew mid-teens excluding COVID [21][22] - Capital equipment revenue returned to growth in the high teens, with orders growing over 20% [12][22] - Consumable revenue and orders, excluding proteins, grew over 20% year-over-year, marking a record revenue quarter on a non-COVID basis [11][24] Market Data and Key Metrics Changes - North America represented 49% of total revenue, Europe 38%, and Asia Pacific 13%, with all regions growing in the mid-teens [27] - Orders from China rebounded to over 40% year-over-year, indicating a significant recovery [28][58] - Emerging biotech revenue grew in the high teens, although orders remained muted [10][60] Company Strategy and Development Direction - The company aims to be the global innovation leader in bioprocessing, focusing on differentiated data-driven solutions across therapeutic modalities [15][16] - Strategic investments are being made in manufacturing labor to serve customers better and preserve lead times [9] - The company plans to double its size in the medium term with modest M&A assumptions, while maintaining profitability and driving gross margin expansion [17][37] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the business momentum, highlighting strong order trends and broad-based demand across the portfolio [8][10] - The company is focused on customer-centric innovation to enable clients to produce therapies more efficiently [10][16] - Despite macro challenges, the company believes it can deliver differentiated growth and outpace industry growth by 5% [17][73] Other Important Information - The company published its 2024 corporate sustainability report, highlighting a 25% reduction in waste generation [20] - The company has taken price actions to offset inflation, resulting in a slight benefit to 2025 revenue [19] Q&A Session Summary Question: Can you elaborate on the growth seen on the clinical trial side versus commercial campaigns? - Management noted very little pull forward in orders, except for a couple of million in China due to tariff uncertainties, and emphasized that the business is still more clinical than commercial [44][45] Question: Can you size your exposure to gene therapy? - Management indicated minimal incremental revenue expected from the gene therapy platform for the remainder of 2025, representing a 1% headwind versus prior guidance [48][49] Question: What are the trends in capital equipment and China? - Management expressed optimism about capital equipment performance, attributing it to differentiated systems and a strong funnel, while also noting a significant rebound in orders from China [56][58] Question: What is the outlook for new modalities? - Management acknowledged a muted outlook for new modalities in the second half but emphasized strong growth in other areas, compensating for the headwind from gene therapy [66][68] Question: What is the expected market growth? - Management estimates market growth to be between 8% to 12%, with confidence in achieving growth above market levels [72][74]

Financial Data and Key Metrics Changes - The company reported second quarter revenue of $182 million, reflecting a 15% increase year-over-year, with an 11% organic growth excluding acquisitions and currency effects, and a 17% organic non-COVID growth [25][26][29] - Adjusted net income was $21 million, a decline of $1 million year-over-year, impacted by lower interest income and higher tax provisions [31] - Adjusted fully diluted earnings per share for the second quarter were $0.37, down 6% from $0.40 in the same period in 2024 [32] Business Line Data and Key Metrics Changes - Chromatography revenue grew over 40%, driven by large-scale column demand from Pharma and Europe [21] - Filtration revenue grew mid-teens, with strong orders and a record quarter for ATF order intake [20] - Capital Equipment revenue returned to growth in the high teens, with orders growing over 20% [10][11] Market Data and Key Metrics Changes - BioPharma revenues grew 20% year-over-year, with strong performance from large pharma accounts [9][10] - Orders from China rebounded significantly, growing over 40% year-over-year, indicating a potential recovery in the region [26][60] - Emerging Biotechs saw revenue growth in the high teens, although orders remained muted [10][62] Company Strategy and Development Direction - The company aims to be a global innovation leader in bioprocessing, focusing on differentiated data-driven solutions across therapeutic modalities [14][15] - Strategic investments are being made in manufacturing labor to meet customer demand and preserve lead times [7] - The company plans to double its size in the medium term with modest M&A assumptions, while maintaining profitability and driving gross margin expansion [16][37] Management Comments on Operating Environment and Future Outlook - Management remains optimistic about the momentum in business, highlighting strong order trends and broad-based demand across the portfolio [6][9] - The company is focused on delivering on its strategy despite macroeconomic challenges, emphasizing customer-centricity and innovation [8][15] - Future growth opportunities are seen in Asia, new modalities like ADCs and cell therapy, and trends like digitization [15][16] Other Important Information - The company published its 2024 corporate sustainability report, highlighting a 25% reduction in waste generation [19] - The company has taken price actions to offset inflation, resulting in a slight benefit to 2025 revenue [18] Q&A Session Summary Question: Can you elaborate on the growth seen on the clinical trial side versus commercial campaigns? - Management noted very little pull forward in orders, except possibly a couple of million in China due to tariff uncertainties [45][46] Question: What is the exposure to gene therapy platforms? - Management indicated minimal incremental revenue expected from the gene therapy platform for the remainder of 2025, representing a 1% headwind versus prior guidance [50][51] Question: Can you discuss the strength in capital equipment and the situation in China? - Management expressed optimism about capital equipment performance and noted a significant rebound in orders from China, attributing it to new leadership and innovation [58][60] Question: What is the outlook for new modalities? - Management expects muted demand in the second half for new modalities but remains confident in overall portfolio strength compensating for this headwind [70][71] Question: What is the expected market growth and the company's growth strategy? - Management estimates market growth at 8-12% and believes the company can outpace this by 5% through a diversified approach across multiple modalities and customers [74][76]

Core Insights - Repligen Corporation reported first-quarter 2025 adjusted earnings per share of 39 cents, exceeding the Zacks Consensus Estimate of 35 cents and up from 30 cents in the same quarter last year [1][5] - Total revenues reached $169 million, reflecting a 10% year-over-year increase, and an 11% organic growth when excluding acquisition and currency impacts, surpassing the Zacks Consensus Estimate of $164 million [2][6] - The company anticipates total revenues for 2025 to be between $695 million and $720 million, slightly higher than previous guidance, while adjusted EPS is expected to be between $1.63 and $1.72, down from earlier estimates [10][11] Financial Performance - Product revenues were $169.1 million, marking a 10.5% increase from the previous year, while royalty and other revenues decreased by 2.7% to $0.04 million [5][6] - Adjusted gross margin improved to 53.7% from 49.2% year-over-year, with adjusted operating income rising to $23.4 million compared to $13.6 million in the prior year [8][9] - Total orders grew nearly 20%, with all four business franchises experiencing double-digit growth [6] Business Segments - Revenues from biopharma and consumables increased by over 20% year-over-year, driven by strong orders, although CDMO sales saw a slight decline [7] - The company reported 14% organic non-COVID revenue growth for the first quarter, indicating robust performance in its core business segments [6] Guidance and Outlook - Repligen expects adjusted gross margin for 2025 to be between 52% and 53%, reflecting a 100 basis point increase from previous expectations [11] - The updated guidance incorporates the impact of the acquisition of 908 Devices' bioprocessing analytics business, which aims to enhance Repligen's process analytical technology portfolio [11] - The company reiterated its organic revenue growth guidance for 2025 in the range of 9.5% to 13.5% [11]

Core Insights - Enzo Biochem, Inc. has qualified to trade on the OTCQX Best Market, transitioning from the New York Stock Exchange [1][2] - The OTCQX Market provides companies with efficient and cost-effective access to U.S. capital markets, with streamlined requirements aimed at reducing costs and complexity for public trading [3] Company Overview - Enzo Biochem, Inc. has been a life sciences company for over 45 years, focusing on labeling and detection technologies, with a comprehensive portfolio of thousands of high-quality products [5] - The company's primary business is conducted through its Life Sciences division, which plays a central role in translational research and drug development [5] Market Context - OTC Markets Group Inc. operates regulated markets for trading 12,000 U.S. and international securities, with data-driven disclosure standards forming the foundation of its public markets [6] - The OTC Link Alternative Trading Systems provide critical market infrastructure for broker-dealers, facilitating trading and offering companies more efficient access to U.S. financial markets [7]